Dr. Julie Hambleton is a highly experienced biotechnology executive with more than 25 years of leadership across clinical development, regulatory strategy, and company building, spanning preclinical research through Phase 4 studies, product approvals, and post-marketing activities. She brings deep expertise in oncology drug development, capital markets, and governance, having served in senior executive and board roles across both public and private biotechnology companies.

Dr. Hambleton previously held senior leadership roles including Chief Medical Officer and Head of Development at IDEAYA Biosciences, Executive Vice President and Chief Medical Officer at Five Prime Therapeutics, and Vice President and Head of U.S. Medical Affairs at Bristol Myers Squibb. Earlier in her career, she spent several years at Genentech in global clinical development leadership roles. She has been involved in multiple successful INDs, BLAs, regulatory interactions with the U.S. Food and Drug Administration and European Medicines Agency, and the approval of several oncology products.

She currently serves on the boards of Erasca, Inc., a NASDAQ-listed company, and privately-held Accent Therapeutics and Onc.AI. She previously served as Director on the Board at Springworks Therapeutics until its acquisition by Merck KGaA.

Dr. Hambleton received her M.D. from Case Western Reserve University School of Medicine and completed her medical and hematology-oncology training at the University of California, San Francisco, where she also served on faculty. She holds a B.S. from Duke University and is board-certified in hematology and internal medicine.